Vitadrip IV Therapy Ventures, LLP – Trademark Portfolio
Entity Type: 21
Vitadrip IV Therapy Ventures, LLP holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. The portfolio also extends into Class 25 (Clothing) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include VITADRIP and VITADRIPIV. The owner is based in Tomball, TX.
13622 Country Time Cir
Tomball, TX 77375
Showing of trademarks Trademarks
Trademark Classifications
Vitadrip IV Therapy Ventures, LLP's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Vitadrip IV Therapy Ventures, LLP have?
Vitadrip IV Therapy Ventures, LLP has 5 U.S. trademarks filed with the USPTO. Of these, 3 registered, 2 cancelled.
What trademark classes does Vitadrip IV Therapy Ventures, LLP file in?
Vitadrip IV Therapy Ventures, LLP files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 25 (Clothing), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Vitadrip IV Therapy Ventures, LLP's most well-known trademarks?
Vitadrip IV Therapy Ventures, LLP's registered trademark portfolio includes well-known marks such as VITADRIP and VITADRIPIV. These are among 3 currently registered trademarks in the portfolio.
What is Vitadrip IV Therapy Ventures, LLP's trademark registration success rate?
Vitadrip IV Therapy Ventures, LLP has a 60% trademark registration rate, with 3 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.